Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 2, 2014, Pages 227-236

  Campbell, Jonathan D ^a   Ghushchyan, Vahram ^a   Brett McQueen, R ^a   Cahoon Metzger, Sharon ^b   Livingston, Terrie ^b   Vollmer, Timothy ^c   Corboy, John ^c   Miravalle, Augusto ^c   Schreiner, Teri ^c   Porter, Victoria ^d   Nair, Kavita ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b BIOGEN   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Burden of illness; Direct costs; MEPS; Multiple sclerosis; Quality of life; Reduced productivity

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DISEASE ASSOCIATION; EMPLOYMENT STATUS; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT ASSESSMENT; PREVALENCE; QUALITY OF LIFE; SHORT FORM 12; SHORT FORM 6 DIMENSION; SOCIAL STATUS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

EID: 84892808157     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2013.09.004     Document Type: Article

References (51)

1. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. 〈http://meps.ahrq.gov/mepsweb/⌠[accessed 08.02.13].
2. D. Anderson, S. Dumont, P. Jacobs, and L. Azzaria The personal costs of caring for a child with a disability: a review of the literature Public Health Reports 122 2007 3 16
3. D.W. Anderson, J.H. Ellenberg, C.M. Leventhal, S.C. Reingold, M. Rodriguez, and D.H. Silberberg Revised estimate of the prevalence of multiple sclerosis in the United States Annals of Neurology 31 3 1992 333 336
4. C.V. Asche, M.E. Singer, M. Jhaveri, H. Chung, and A. Miller All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States Journal of Managed Care Pharmacy 16 2010 703 712
5. H.M. Baum, and B.B. Rothschild The incidence and prevalence of reported multiple sclerosis Annals of Neurology 10 5 1981 420 428
6. J. Brazier, and J. Roberts The estimation of a preference-based measure of health from the SD-12 Medical Care 42 2004 851 859
7. R.J. Buchanan, R.A. Martin, W. Suojin, and MyungSuk Kim Racial analysis of longer stay nursing home residents with multiple sclerosis Ethnicity & Disease 16 2006 159 165
8. R.J. Buchanan, D. Radin, and C. Huang et al. Caregiver perceptions associated with risk of nursing home admission for people with multiple sclerosis Disability and Health Journal 3 2010 117 124
9. I. Casetta, T. Riise, and M. Wamme Nortvedt et al. Gender differences in health-related quality of life in multiple sclerosis Multiple Sclerosis 15 2009 1339 1346
10. Chronic Conditions Indicator for ICD-9-CM. 〈http:// www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp⌠[accessed 26.08.12].
11. J.W. Cohen, S.B. Cohen, and J.S. Banthin The Medical Expenditure Panel Survey: a national information resource to support healthcare cost research and inform policy and practice Medical Care 47 2009 S44 S50
12. M. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
13. L.D. Goldberg, N.C. Edwards, and C. Fincher et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis Journal of Managed Care Pharmacy 15 2009 543 555
14. C. Heesen, L. Nawrath, and C. Reich et al. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? Journal of Neurology, Neurosurgery, and Psychiatry 77 2006 34 39
15. J.I. Ivanova, R.E. Bergman, and H.G. Birnbaum et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US Journal of Medical Economics 15 2012 601 609
16. J.I. Ivanova, H.G. Birnbaum, and S. Samuels et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US Pharmacoeconomics 27 2009 681 691
17. E. Kingwell, M. van der Kop, and Y. Zhao et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada Journal of Neurology, Neurosurgery, and Psychiatry 83 2011 61 66
18. G. Kobelt, J. Berg, and D. Atherly et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States Neurology 66 2006 1696 1702
19. G. Kobelt, J. Berg, and P. Lindgren et al. Costs and quality of life of patients with multiple sclerosis in Europe Journal of Neurology, Neurosurgery, and Psychiatry 77 2006 918 926
20. S. Lee, D.C. Baxter, and B. Limone et al. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States Journal of Medical Economics 15 2012 1088 1096
21. Y. Li, K.L. Munger, and S. Batool-Anwar et al. Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women Neurology 78 2012 1500 1506
22. I. Loma, and R. Heyman Multiple sclerosis: pathogenesis and treatment Current Neuropharmacology 9 2011 409 416
23. W.T. Mayr, S.J. Pittock, R.L. McClelland, N.W. Jorgensen, J.H. Noseworthy, and M. Rodriguez Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000 Neurology 61 10 2003 1373 1377
24. R.J. Mills, and C.A. Young The relationship between fatigue and other clinical features of multiple sclerosis Multiple Sclerosis 17 2011 604 612
25. T.J. Morrow The costs and consequences of multiple sclerosis relapses: a managed care perspective [published online ahead of print March 23, 2007] Journal of the Neurological Sciences 256 Suppl. 1 2007 S39 S44
26. National MS Society. 〈http://www.nationalmssociety. org/about-multiple-sclerosis/relapsing-ms/relapsing-remitting-ms-rrms/ how-rrms-differs-from-progressive-courses-of-ms/index.aspx⌠[accessed 08.02.13].
27. National Multiple Sclerosis Society. Who gets MS? 〈 http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/ who-gets-ms/index.aspx⌠[accessed 20.09.11].
28. P.J. Neumann, and D. Greenberg Is the United States ready for QALYs? Health Affairs (Millwood) 28 2009 1366 1371
29. C.W. Noonan, S.J. Kathman, and M.C. White Prevalence estimates for MS in the US and evidence of an increasing trend in women Neurology 58 2002 136 138
30. C.W. Noonan, D.M. Williamson, J.P. Henry, R. Indian, S.G. Lynch, and J.S. Neuberger et al. The prevalence of multiple sclerosis in 3 US communities Preventing Chronic Disease 7 2010 1
31. D.E. Northrop, and D. Frankel Nursing home care of individuals with multiple sclerosis: guidelines and recommendations for quality care. Monograph 2009 National Multiple Sclerosis Society Professional Resource Center, New York, NY
32. S. Olofsson, A. Wickstrom, and A. Hager Glenngard et al. Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 years of treatment BioDrugs 25 2011 299 306
33. E. Orlewska Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies? Expert Review of Pharmacoeconomics and Outcomes Research 6 2006 145 154
34. S.M. Orton, B.M. Herrera, and I.M. Yee et al. Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study Lancet Neurology 5 2006 932 936
35. M.B. Patwardhan, D.B. Matchar, G.P. Samsa, D.C. McCrory, R.G. Williams, and T.T. Li Cost of multiple sclerosis by level of disability: a review of literature Multiple Sclerosis 11 2005 232 239
36. C.J. Phillips The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment CNS Drugs 18 2004 561 574
37. J.D. Prescott, S. Factor, and M. Pill et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database Journal of Managed Care Pharmacy 13 2007 44 52
38. K. Rajagopalan, R.A. Brook, and I.A. Beren et al. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation Current Medical Research and Opinion 27 2011 179 188
39. J. Sellner, J. Kraus, and A. Awad et al. The increasing incidence and prevalence of female multiple sclerosis - a critical analysis of potential environmental factors Autoimmunity Reviews 10 2011 495 502
40. S.C. Steinberg, R.J. Faris, and C.F. Chang et al. Impact of adherence to interferons in the treatment of multiple sclerosis Clinical Drug Investigation 30 2010 89 100
41. K.A. Stopl-Smith, E.J. Atkinson, M.E. Campion, P.C. O'Brien, and M. Rodriguez Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN Neurology 50 1998 1594 1600
42. M. Trisolini, A. Honeycutt, A. Wiener, and S. Lesesne Global economic impact of multiple sclerosis 2010 (Multiple Sclerosis International Federation) Prepared by RTI Research Triangle Park
43. United States Census Bureau. Income data. Available from: 〈http://www.census.gov/hhes/www/income/data/⌠[accessed 26.08.12].
44. US Department of Labor. Bureau of Labor Statistics. Consumer Price Index. 〈http://www.bls.gov/cpi/⌠[accessed 26.08.12].
45. A. Vlahiotis, R. Sedjo, and E.R. Cox et al. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients Journal of Managed Care Pharmacy 16 2010 206 216
46. J. Ware Jr., M. Kosinski, and S.D.A. Keller 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity Medical Care 34 1996 220 233
47. D.M. Williamson, and J.P. Henry Challenges in addressing community concerns regarding clusters of multiple sclerosis and potential environmental exposures Neuroepidemiology 23 5 2004 211 216
48. B. Wood, I. van der Mei, and A.L. Ponsonby et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis Multiple Sclerosis 19 2013 217 224
49. A. Wundes, T. Brown, and E.J. Bienen et al. Contribution of intangible costs to the economic burden of multiple sclerosis Journal of Medical Economics 13 2010 626 632
50. D. Yamamoto, and J.D. Campbell Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature Autoimmune Diseases 2012 784364 10.1155/2012/784364 (Epub 2012 December 6)
51. H.L. Zwibel, and J. Smrtka Improving quality of life in multiple sclerosis: an unmet need American Journal of Managed Care 17 Suppl. 5 2011 S139 S145